Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
Case Comprehensive Cancer Center
Study ID
NCT04332341
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Allogeneic Hematopoietic Cell Transplantation

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nicotinamide riboside (NR) — DRUG
    Nicotinamide riboside, PO, 500mgtwice daily for 21, 28, and 35 days

Study Details

The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.

Key Dates

Start date
May 19, 2020
Status verified
Jun 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nicotinamide riboside (NR)

Primary Outcome Measure

Percent of participants who receive >75% of scheduled doses. [ Time Frame: day +7 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cleveland Clinic, Case Comprehensive Cancer CenterClevelandOhio44195
Navneet Majhail, MD
[email protected]
866-223-8100
Navneet Majhail, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cleveland, OH

By research site
Cleveland Clinic, Case Comprehensive Cancer Center· Cleveland, OH

Related Studies